Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
277 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07003321 | A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07232849 | A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 12, 2025 |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | active not recruiting | Phase 3 | 423 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07238283 | Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer | recruiting | Phase 3 | 662 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06735144 | Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07134998 | Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations | recruiting | Phase 1 | 153 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06925581 | A Trial of HRS-6768 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 84 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05945901 | A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 669 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07175220 | Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects | recruiting | Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05367687 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | completed | Phase 2 | 251 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07051486 | A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer | recruiting | Phase 2 | 60 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07142980 | A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications | recruiting | Phase 1 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04619433 | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. | terminated | Phase 3 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06520488 | A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 118 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06385678 | A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | active not recruiting | Phase 1 / Phase 2 | 47 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04446260 | A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 5 | Sep 15, 2025 | clinicaltrials |
| NCT06949124 | A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07014488 | A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects | completed | Phase 1 | 16 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07102901 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 351 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | active not recruiting | Phase 3 | 443 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05533463 | Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | active not recruiting | Phase 1 | 102 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06689163 | A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone | recruiting | Phase 1 / Phase 2 | 66 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT02834936 | A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation | completed | Phase 2 | 60 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03588091 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | completed | Phase 3 | 355 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05208177 | A Study of SHR-1802 in Patients With Advanced Solid Tumor | terminated | Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05424835 | A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | active not recruiting | Phase 3 | 381 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06969664 | A Trial of SHR7280 in Healthy Subjects | completed | Phase 1 | 16 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07070349 | A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06254742 | A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies | withdrawn | Phase 3 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT04680988 | A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 194 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT04571710 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT05983146 | Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies | withdrawn | Phase 1 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT07056439 | Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 50 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT03777124 | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03863860 | A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients | completed | Phase 3 | 252 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT04400188 | A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | terminated | Phase 2 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03976882 | Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. | completed | Phase 3 | 129 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT04796948 | A Study of Irinotecan Liposome in Advanced Pancreatic Cancer | completed | Phase 1 | 41 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05864014 | Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. | active not recruiting | Phase 3 | 213 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05473624 | Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 153 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06906731 | A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 27 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06783829 | A Study of SHR-4394 Injection in Subjects With Prostate Cancer | recruiting | Phase 1 | 240 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04517357 | A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | completed | Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04869488 | A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 93 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT05799183 | A SHR-1210 BE Study on Healthy Subjects | terminated | Phase 1 | 12 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT03603951 | A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms | active not recruiting | Phase 1 | 272 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05048134 | A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies | terminated | Phase 1 | 13 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials